452PD - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results. - Voskoboynik, M.; Mileshkin, L.; Gan, H.; Millward, M.; Au-Yeung, G.; Meniawy, T.M.; Kichenadasse, G.; Zhang, K.; Zhang, M.; Mu, S.; Lickliter, J.D. (Annals of Oncology, 2019)